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Effects of graded oxygen tension on adenosine release by renal medul-
lary and thick ascending limb suspensions. Adenosine is released from
renal cells, and extracellular adenosine may influence the effects of
ischemia on medullary tubule segments by altering ion transport or
renal hemodynamics. While adenosine release and excretion are en-
hanced during renal ischemia, the specific sites of renal adenosine
production have not been completely elucidated. In the present study,
extracellular adenosine concentrations in suspensions of renal outer
medulla and thick ascending limb segments were quantitated by re-
versed-phase high performance liquid chromatography. Media from
other medullary (OM) suspensions incubated for 8 and 15 minutes at 0%
oxygen contained significantly greater amounts of adenosine (1 .404
0.21 and 2.034 0.27 ng/jg protein, respectively), when compared to
values obtained from media of suspensions incubated for equivalent
periods under non-hypoxic conditions (8, 20, and 95% oxygen), 0.78
0.05 (8 mm) and 1.37 0.21 ng/g protein (15 mm). Similarly,
adenosine release was greater in medullary thick ascending limb
(mTAL) suspensions incubated for 8 minutes at 0% versus 8% oxygen
(0.81 0.17vs. 0.20 0.12 ng/pg protein,respectively). Moreover, the
observed increase in adenosine release by thick ascending limbs at 0%
oxygen could be inhibited completely by either furosemide or ouabain.
These studies demonstrate that: 1) the renal medulla and medullary
thick ascending limb are sites of adenosine release; 2) adenosine release
by the mTAL is enhanced significantly during hypoxic conditions; and
3) the increased release of adenosine during hypoxia appears to be
related to ion transport and oxidative metabolism, as the increased
release was prevented by two disparate inhibitors of transport in this
segment.
Adenosine (ADE) has been identified as a modulator of
regional blood flow in a variety of tissues [1—3j and has been
proposed as a potential regulator that balances cellular oxygen
demands with delivery [4]. This regulatory balance may also be
operative in ischemic renal injury based on the following
observations.
Reduced oxygen delivery to the kidney produces prolonged
impairment of normal hemodynamic and transport function
which culminates clinically in the development of acute renal
failure [5—7]. The nephron segments most susceptible to this
damage are variable and depend on the degree of compromise in
oxygen delivery to these segments. During selective reduction
in oxygen delivery alone (not combined ischemia and anoxia)
the S3 segment of the proximal straight tubule and the medul-
lary TAL have been shown to be particularly vulnerable to
injury [8—10]. Studies have suggested that nephron segments in
the outer medulla may be particularly vulnerable to injury
because oxygen tension and blood flow to that region are low
under physiologic conditions [11, 12]. Both parameters are
further reduced by transient hypoxia or decline in blood flow [5,
13, 14]. In addition, however, ischemic damage to these neph-
ron segments can be ameliorated by a reduction in transport-
related 02 consumption, as occurs during decreased solute
delivery, inhibition of active sodium reabsorption, or by main-
tenance of cellular ATP concentrations [15—171. Inhibition of
transport-related oxygen consumption in the mTAL reduces
total oxygen consumption to less than 50% [18]. This segment
has also been shown to exhibit significant energy expenditure
and maintain cellular ATP stores by anaerobic metabolism [19].
It follows, therefore, that the viability of this segment may be
preserved if transport-related 02 consumption is inhibited dur-
ing hypoxia or ischemia.
ADE could be importantly involved in the response of these
nephron segments to ischemic or hypoxic damage for the
following reasons: 1) ADE is a byproduct of normal ATP
hydrolysis or cellular energy-dependent processes [20, 211;
intracellular and extracellular concentrations of ADE are in-
creased by a reduction in 02 availability for oxidative phosphor-
ylation in a variety of cells [1, 20—23]. 2) ADE excretion in the
urine and renal ADE content is increased during hypoxia or
ischemia [22, 24]. 3) Extracellular ADE exerts a variety of renal
actions including a reduction in total renal blood flow [25—27],
an alteration in renal blood flow distribution resulting in a
relative increase in medullary blood flow [11, 28], a reduction in
glomerular filtration rate [26, 27, 29, 30], inhibition of renin
release [25, 27, 30], and inhibition of epithelial transport of
chloride in the shark rectal gland [31] and the rat superficial
"loop segment" in vivo [321. ADE receptors appear to mediate
these renal effects, as suggested by the effects of A1 and A2
analogues on renal hemodynamics and transport [25—27, 301. 4)
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The portion of the nephron between the late proximal convoluted
tubule and the earliest segment of the distal tubule accessible to
micropuncture.
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Content mM A
NaCI 115
NaHCO3 25
NaH2PO4 0.2
KCL 8.0
CaCI2 0.25
MgSO4 1.0
Na lactate 5.0
1-Alanine 1.0
Glucose 5.0
Dextran 0.3%
Mannitol 25
Dipyridamole —
EHNA (see text) —
Finally, and more specifically, inhibition of enzymatic degrada-
tion of adenosine during renal ischemia prevents a further
decline in GFR (which is associated with tubular ischemia, cell
sloughing, and tubular obstruction) during the maintenance
phase of ischemic acute renal failure [33]. These findings
suggest that increased ADE release could ameliorate hypoxic!
ischemic damage to the medullary loop segments in several
ways, such as, improving medullary 02 delivery, inhibiting
transport-related 02 consumption, or decreasing the delivery of
solute by reduction in GFR (during the initiation phase of
ischemic injury) to the loop segments. The specific iñtrarenal
site(s) of ADE production during normal metabolism or during
ischemia-mediated augmentation are not presently known.
The present studies were designed, therefore, to determine
directly whether the outer medulla and mTAL are sites of renal
ADE release and, if so, whether ADE release is affected by
hypoxia. The results show that ADE is released by both crude
outer medullary suspensions and by suspensions enriched in
mTAL. Furthermore, in both OM and mTAL, the release of
ADE was enhanced by hypoxia. In the mTAL, furosemide or
ouabain prevented completely the enhanced ADE release dur-
ing hypoxia, suggesting that ADE release is dependent upon
epithelial transport and, presumably, oxygen consumption.
Methods
All studies were performed on male Sprague-Dawley rats
(Taconic Farms, Germantown, New York, USA), 250 to 350
grams, that received standard rat chow (Purina, St. Louis,
Missouri, USA) and tap water ad lib.
Suspensions of OM and mTAL
Suspensions of mTAL and outer medulla (OM) were pre-
pared by the method of Chamberlain, Le Furgey and Mandel
[18], with minor modifications. Briefly, following anesthesia,
the kidneys were perfused retrograde through the aorta with a
hypertonic mannitol solution (Solution A, Table 1) at 0 to 4°C
until the kidneys were completely blanched of blood and brisk
urine flow was established. The kidneys were removed, and the
inner stripe of the outer medulla dissected free and minced. The
minced tissue was digested at 37°C for three ten-minute periods
in Solution A that contained 110 U/mI collagenase Type IV and
297 U/mI hyaluronidase. The digestion solution was stirred
continuously and bubbled with 95% 02/5% CO2. Following
Table 2. Cyclic AMP production in response to hormones of
medullary thick ascending limb suspensions
______
pmol cAMP/mg proteinl3Omm
Control
PTH 106 M
AVP 1 pJml
Calcitonin 3 X 1O M
Glucagon 10° M
Values are expressed as means SEM. Abbreviations are: PTH,
parathyroid hormone; AVP, arginine vasopressin.
P < 0.05 compared to control values, unpaired Student's t-test
each of the digestion periods, the digested material was filtered
through a 105 m polypropylene filter (Spectrum, Los Angeles,
California, USA). At the end of the third digestion period, the
suspension was aspirated repeatedly through an 18 gauge
needle to separate completely any remaining tissue aggregates.
This tissue was washed and kept at 0 to 4°C as the OM
suspension. The tissue collected in the first two digestion
periods was pooled, washed in Solution A, and used to prepare
the mTAL suspension. The mTAL were enriched by differential
gradient centrifugation with Percoll and collected and washed in
Solution B (Table 1). The final pellet was resuspended in the
incubation solution (Table 1) and kept at 0 to 4°C until used. An
aliquot of each suspension was removed and protein concen-
tration determined by the Lowry et al method 1341 for standard-
ization of adenosine release.
Previous studies have shown enrichment of mTAL obtained
from this technique and have demonstrated active transport as
determined by ouabain and furosemide inhibitable oxygen
consumption [18]. In the present study, enrichment and viabil-
ity of mTAL in the final suspension was assessed further by the
following methods:
1) Light microscopy. Examination of the suspension revealed
a homogenous tubule population with few single cells and
minimal cellular debris. Tubules with open lumens constituted
more than 95% of all tubules and greater than 90% of the tubules
were mTAL.
2) Electron microscopy. Under higher magnification, 2,000X
to l0,000x, the tubule cells demonstrated extensive lateral
cellular interdigitation, abundant mitochrondria prevalent in the
basal portion primarily, and scant luminal microvilli indicative
of cells of medullary thick ascending limbs. In addition, little
cellular vacuolization or nuclear clumping suggestive of isch-
emic damage was present.
3) Hormonal responsiveness of cyclic AMP production. To
demonstrate enrichment of mTAL suspensions in our prepara-
tion, cyclic AMP production was assessed according to the
method of Harper and Brooker [35] using a competitive radio-
immunoassay with '25-I-cyclic AMP. As shown in Table 2, the
enriched mTAL suspension increased cyclic AMP production
significantly in response to arginine vasopressin (AVP), calci-
tonin, and glucagon, but not to parathyroid hormone (PTH).
This is the same pattern of hormone responsiveness demon-
strated by Morel et al in isolated mTAL segments [36] and by
Chamberlain et al in mTAL suspensions [18]. The stimulation Of
cyclic AMP production was less in the present studies because
phosphodiesterase inhibitors were not included in the incuba-
tion media.
Table 1. Composition of solutions
Solutions
B Incubation fluid
115
25
0.2
8.0
0.25
1 0
10
0.6%
30
115
25
2.0
5.0
1.0
1.0
5.0
l0
0.02
0.01
453.4 49.1
518.2 56.1
1327.9 l43.8a
1425.1 l54.3'
1360.1 147.1°
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4) Lactate dehydrogenase (LDH) release. As a measure of
cell membrane integrity, LDH concentrations in the incubation
fluid were determined at the end of incubation periods using the
colorimetric method of Cabaud and Wroblewski [371. In sam-
ples (N = 22) exposed to 0 to 95% 02 for up to 15 minutes, the
supernatant LDH values were undetectable (<10 U/mi),
whereas in disrupted cellular suspensions LDH values were 70
U/mi.
5) Dye exclusion. Further validation of cell membrane integ-
rity was assessed by incubation of suspensions of OM for eight
minutes at 0 and 95% 02 followed by incubation with trypan
blue. A total of 100 cells were totaled in four individual
suspensions incubated under the two oxygen concentrations.
Seven percent of the cells under hypoxic conditions failed to
exclude the dye as opposed to 6% when incubated with 95% 02.
6) Inhibition of ADE release during hypoxia by inhibitors of
ion transport. Furosemide and ouabain completely ameliorated
the increment in ADE release by mTAL suspensions (Results),
indicating that ADE release can be regulated and, therefore, is
not a non-specific release of ADE from cells due to cell damage
during preparation.
Incubation protocol
Incubation fluid (Table 1), 0.8 ml aliquots, containing dipyr-
idamole and erythro-9-(2-hydroxy-3-nonyl) adenine (EHNA)
was pre-equilibrated for at least 20 minutes with 0, 2, 8, 20, or
95% 0 and 5% CO2 (balance nitrogen). Following this equili-
bration period, 0.1 ml of OM or mTAL suspension was added to
each aliquot and incubated for 0.5, 3, 8, or 15 minutes while
being continuously bubbled with one of the above oxygen
concentrations. At the end of each time period, the incubation
fluid was rapidly filtered through 0.45 HA filters (Millipore,
Bedford, Massachusetts, USA) to separate the supernatant
from the medullary tissue. In addition, a zero time point was
determined to assess if ADE release occurred in the suspension
following the final wash period until incubation was begun. This
was accomplished by addition of 0.1 ml suspension directly into
a syringe containing 0.8 ml incubation fluid and immediately
filtering the solution. No ADE could be detected in these
samples (N 8). To determine if ADE was completely recov-
ered during filtration, incubation fluid containing 3H-adenosine
at a known concentration was filtered in a manner identical to
the experimental samples. Recovery of 3H-adenosine from
these samples was 98%. The experimental samples were stored
at —70°C for less than two weeks until ADE could be quanti-
tated.
Because the incubations procedure allowed a sealed environ-
ment only during the actual incubation and not at the rapid
separation step (open system), oxygen tensions in the suspen-
sions were measured and compared with the nominal oxygen
concentrations. Incubation fluid was rapidly aspirated from test
tubes into sealed glass syringes and immediately analyzed on a
Corning Blood Gas Analyzer Model 165/2 (Medfield, Massachu-
setts, USA) calibrated using 0 and 20% 02 standards. Oxygen
tension measured in fluid equilibrated with nominally 0% 02
was 16 mm Hg (2.2%), 2% 02 = 36 mm Hg (5%), 8% 02 = 61
mm Hg (8.2%), 20% 02 = 142 mm Hg (19.5%), 95% 02 = 594
mm Hg (82.5%). The small differences between measured and
nominal values presumably reflect gain or loss of 02 from the air
due to the partially open system. Nominal values are used in the
text for simplicity.
Adenosine quantitation
ADE was separated and quantified by reversed-phase, ion-
pairing HPLC as described by Bodola and Benedict [381.
Briefly, 10 pi sample of standard solution or incubation fluid,
without an internal standard, was injected into a Brownlee
RP-l8 column (Santa Clara, California, USA) loaded with a
mobile phase, buffered to pH 6.5 with 8 N KOH, consisting of
0.125 M KH2PO4, 1.5% vol/vol acetonitrile, 12.5 mM triethyl-
amine, and 4 msi tetrabutylammonium. Adenosine was de-
tected by a Kratos Spectroflow 783 UV spectrophotometer
(Kratos Analytical, Ramsey, New Jersey, USA) at 259 nm and
collected and analyzed with a IBM PC/XT and Nelson Analyt-
ical 2600 Series Chromatography software (Cupertino, Califor-
nia, USA). Samples were injected into the column at 0.5 mLlmin
at a pressure of 2600 psi. Standards prepared by dissolving
adenosine in incubation fluid were assayed to determine a
standard curve, resolution, and retention time. Standard curves
were linear for 0 to 10 ng adenosine, with an r value of >0.98.
Interassay variability was 4% and the detection limit for aden-
osine was >0.2 ng. The retention time for adenosine was 5.9
minutes. To verify that adenosine was resolved from related
compounds, standards for inosine and hypoxanthine also were
measured. Inosine was resolved at 2.6 minutes and, thus, did
not overlap or interfere with ADE. Hypoxanthine could not be
resolved as the peak came off early and the absorbance was
obscured by other compounds in the incubation fluid with little
retention on the column. Previous results have shown that ADP
and ATP have a longer retention time [41 and were not detected
over the resolution periods of eight minutes used in the present
studies.
Collagenase, hyaluronidase, dipyridamole, and ouabain were
obtained from Sigma Chemicals (St. Louis, Missouri, USA).
Furosemide was obtained from Hoechst-Roussel (Somerville,
New Jersey, USA) EHNA was a gift from Weilcome Research
Laboratories (Research Triangle Park, North Carolina, USA).
ADE concentrations from OM suspensions were analyzed by
ANOVA for time and oxygen concentration and differences
between means were compared by Newman-Keuls multiple
comparison procedure. Results obtained with mTAL suspen-
sions were compared using either unpaired Student's i-test or
ANOVA with Dunnett's multiple comparisons test, as appro-
priate. Differences between means were considered significant
at the P < 0.05 level.
Results
Outer medullary suspension
ADE release was measured in OM suspensions incubated
with 0, 2, 8, 20, or 95% 02 for 0.5, 3, 8, and 15 minutes. These
oxygen concentrations were chosen to approximate tissue P°2
during hypoxia, 0 and 2% normal medullary 02 tension, 8%;
normal systemic 02 tension, 20%; and maximal 02 tension,
95%. Table 3 shows adenosine concentrations measured in
incubation fluid at each time period for each 02 concentration.
As seen in this table, ADE concentrations after 8 and 15
minutes were significantly greater in incubation fluid of suspen-
sions maintained with 0% 02 than in fluid from suspensions at 8,
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Table 3. The effect of graded oxygen tension on adenos
suspensions of rat outer renal medulla
me release in
Nominal
oxygen
concentration
ng adeno-
sine//.Lg
protein
Time of incubation mm
0.5 3 8 15
1.34 0.32"95% 0.21 0.07 0.51 0.07 0.86 0.14
20% 0,12 0.05 0.61 0.14 0.84 0.14 1.37 0.20"
8% 0.21 0.08 0.57 0.03 0.72 0.09" 1.54 0.26"
2% 0.25 0.09 0.37 0.12" 1.09 0.15 1.68 0.25"
0% 0.39 0.10 0.48 0.19 1.40 0.2la 2.03 027a.b
N = 5 to 13 determinations at each time period and 02 concentration.
The release rate (ng/min) of adenosine was significantly greater in each
time period as compared to the preceding period except for values
indicated by bANOVA for repeated measures.
a P < 0.05 compared to 8, 20, and 95% °2, ANOVA with Dunnett's
multiple comparisons test
Fig. 1. Time course of adenosine release in renal outer medullary
suspensions, As the values obtained from suspensions incubated in 8,
20, and 95% 02 (non-hypoxic, ) were not different, the results were
averaged and compared to the values obtained from suspensions
incubated at 0% 02 (hypoxic, 0). N = 6 to 31 determinations at each
time point and 02 concentration. *D < 0.02 and ** < 0.05, ANOVA
with Dunnett's multiple comparisons test.
20, or 95% 02. Secondly, values obtained at any given time
point with 8, 20, and 95% 02 did not differ. Lastly, values for
samples incubated at 2% 02 were intermediate between those at
0% and 8%. Since the values obtained at 8, 20, and 95% 02 were
not significantly different, these values were averaged, and the
time course of ADE concentrations at these "non-hypoxic"
levels was compared with values obtained under hypoxic
conditions, 0% 02 (Fig. 1).
In the above studies, adenosine release was measured in the
presence of EHNA to inhibit adenosine deaminase degradation
of adenosine and dipyridamole to inhibit reuptake of released
adenosine. The rationale for this approach was to maximize
extracellular accumulation of adenosine to facilitate quantifica-
tion in samples likely to contain minute amounts of ADE so as
to ascertain any significant differences between incubation
protocols. As significant and easily quantifiable amounts of
adenosine were released from the suspensions, studies compar-
ing the influence of EHNA and/or dipyridamole on ADE release
6.0 -
50
EHNA EHNA Dip No
+ Dip inhibitors
Fig. 2. The effect of erythro-9-(2-hydroxy-3-nonyl)adenine (EHNA)
and dipyridamole on adenosine release by renal outer medullary
suspensions incubated at 0% 02. Means SEM are given for four
conditions; EHNA + Dip = EHNA and dipyridamole (dip) present in
the incubation fluid, EHNA = EHNA alone present, Dip =dipyrida-
mole alone present, and no inhibitor = neither dipyridamle nor EHNA
present. < 0.05, EHNA + Dip vs. no inhibitor. N =6 in each group.
from OM suspensions incubated for 15 minutes at 0% 02 were
performed (Fig. 2). Without these agents present, the accumu-
lation of adenosine in the extracellular media was reduced by
approximately 40% from 4.47 0.82 (EHNA & dipyridamole
present) to 2.94 0.52 ng/g protein (neither inhibitor present,
P < 0.05). Values obtained with just EHNA or dipyridmole
present were intermediate between those with both inhibitors
and without either inhibitor, suggesting that the presence of
either inhibitor alone was insufficient to significantly affect
extracellular ADE concentration. The reduction in adenosine
accumulation observed in the absence of EHNA was entirely
accounted for by the acumulation of inosine and hypoxanthine.
These findings suggest that enzymatic degradation and cellular
reuptake may influence extracellular adenosine accumulation
under hypoxic conditions but are not sufficient to prevent
significant extracellular accumulation which is consistent with
previous results under similar conditions [15, 20, 22, 24].
MTAL suspensions
Studies with the mTAL suspensions were performed with 0
and 8% 02 at 8 minutes incubation. These conditions were
chosen based on our observations that ADE levels were max-
imal at 8 minutes (Fig. 1) and on the previous finding that the
normal 02 content in the renal medulla is approximately 8%. At
8% 02, ADE was detected in only 3 of 11 samples, with a mean
not different from zero (0.20 0.12 ng/j.g protein).2 In contrast,
at 0% 02, ADE release was significantly increased (0.81 0.17
ng/g protein, P < 0.02) and ADE was detected in 12 of 15
samples (Fig. 3).
In a final series of experiments, mTAL suspensions were
2 The possibility that the low ADE release was due to insufficient
tissue present in the samples is unlikely because the protein content in
the hypoxic (0% 02) suspensions was similar to that in the non-hypoxic
suspensions, yet the ADE concentration was significantly greater in the
former suspension.
'1)
C
ci,C
cci0
C
ci,0
1±4.0
3.0
2.0
1.0
ci,
0.
C
ci,
Ca0C
a,0
2.4
2.0
1.6
1.2
0.6
0.4
0.0
00.6 3 8 15
Time, minutes
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incubated at 0% 02 in the presence and absence of ouabain, 0.5
m, or furosemide, i0 M, to assess the effects on ADE
release of agents known to inhibit ion transport. As shown in
Figure 4, either ouabain or furosemide completely prevented
the increase in ADE release seen under hypoxic conditions.
Discussion
The present studies were designed to investigate the hypoth-
esis that hypoxia increases ADE release in the renal medulla.
To accomplish this goal we examined the effects of hypoxia on
ADE release by outer medulla and mTAL suspensions by
measuring ADE release during incubation of these suspensions
at graded in vitro oxygen content. The results show that
components of the renal outer medulla release ADE. In addi-
tion, mTAL increased ADE release in response to hypoxia.
Furthermore, the increased ADE release by mTAL under
hypoxic conditions was completely inhibited by either furo-
semide or ouabain, suggesting that the enhanced ADE release
in this segment is related to active ion transport.
The design of the present studies allowed determination of
ADE release by the outer medulla and mTAL as a function of in
vitro oxygen. The oxygen concentrations used in the present
studies are physiologically relevant because in vivo oxygen
tensions previously determined in the renal medulla under
control conditions have ranged from 30 to 60 mm Hg [12]. This
range is comparable to oxygen tensions (61 and 36 mm Hg)
achieved in the present study in suspensions equilibrated with
8% and 2% 02. As shown in Figure 3, further reduction to 16
mm Hg (0% 02), a value comparable to that reported during
hypoxia [12], was associated with an increase in ADE release.
Furthermore, there was no significant difference in the ADE
release from OM suspensions equilibrated with 2, 8, 20, or 95%
02, suggesting that oxygen delivery is sufficient at these con-
centrations to maintain normal energy metabolism. Thus,
across this range of 0 tensions, a sharp dose-response rela-
tionship for hypoxic-induced ADE release is observed with
increased adenosine release occurring only when 02 concentra-
tion was less than 30 mm Hg.
Cellular ADE release could be attributed to several mecha-
nisms. ADE has been shown to be a major metabolite of ATP
hydrolysis. However, the intracellular concentration, and thus
the extracellular concentration, is modified by the reincorpora-
tion of ADE into ATP pools when sufficient 02 is available to
maintain oxidative phosphorylation and binding of free intra-
cellular ADE to 1-homocysteine [39]. These biochemical pro-
cesses limit the free intracellular ADE concentrations and the
transport or diffusion from the cell. ADE is also metabolized
both intra- and extracellularly to inosine by adenosine deami-
nase [211. ADE has been shown to be transported out of certain
cells by specific, inhibitable pathways. For example, 4-ni-
trobenzylthioinosine inhibits ADE transport from the cell while
dipyridamole inhibits both reuptake and release of ADE [20, 23,
40]. Little is known about the regulation of these transport
pathways, however. Finally ADE can also exit cells by simple
diffusion [23]. In the present studies, it seems unlikely that
enhanced diffusion as a result of hypoxic alterations in cell
permeability and integrity can account for the increased extra-
cellular ADE concentrations seen under hypoxic conditions
because of the following findings: 1) LDH release or dye
exclusion, markers of cell membrane damage and increased
permeability, were not altered during hypoxia; 2) transport
inhibitors, furosemide and ouabain, prevented the increased
ADE release seen under hypoxic conditions; and 3) the pres-
ence of dipyridamole in the incubation fluid was necessary to
demonstrate maximal ADE concentrations in the extracellular
media. If an increase in permeability allowed rapid diffusion of
intracellular ADE from the cell, one would not expect that
dipyridamole would have a significant effect on reuptake under
these conditions. Though dipyridamole alone was insufficient to
significantly affect adenosine release, its presence was neces-
sary in conjunction with EHNA to reduce adenosine accumu-
lation in extracellular fluid. This supports the concept that at
N = 151.0
0.8
0.6
• 0.4C
0.2
0.0
Fig. 3. Adenosine release from suspensions of medullary thick ascend-
frtg limbs J.ncLthated far 8 rnittuies linder physiologic (8% 0J and
hypoxic (0% 02) conditions. *D < 0.02, unpaired Student's t-test.
N
1.4
1.2
1.0
0.8
:'
Furosemide Ouabain
iO4 M 0.5mM
Fig. 4. The effect offurosemide or ouabain on adenosine release from
medullary thick ascending limb suspensions.*P < 0.05, unpaired Stu-
dent's t-test for 8% 02 vs. 0% 02. Fur = furosemide and Ouab =
ouabain.
8% °2 0%02 0%02
8%02 0%02
+ +
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least a portion of released adenosine exits from the cell by
pathways inhibited by dipyridamole.
The absolute values for ADE release and obtainable extra-
cellular concentrations in the present study are physiologically
relevant for the following two reasons. First, though obtained in
a closed, in vitro system, extracellular ADE concentration (ito
2 m) is similar to previous reports, including cell cultures, of 1
to 5
.LM from renal and other tissues [1, 201. This is within the
concentration range (1 tM) for observed transport effects in
shark rectal gland [31] and the observed Kd of 39 nM for A1
receptors [26]. Furthermore, the calculated calculated ADE
release from the present studies is 4 to 10 nmol/mg protein,
while the estimated total adenine nucleotide content of these
cells is approximately 20 to 30 nmol/mg protein [22, 24, 41—44].
Therefore, the released ADE was 25 to 30% of the total adenine
nucleotide content. Thus, the present studies show: 1) that the
measured concentrations are in a physiologically important
range that may have effects on solute transport; and 2) that the
contents of the OM suspensions and mTAL release significant
amounts of ADE under hypoxic conditions.
The effect of either furosemide or ouabain to prevent the
increased ADE release by mTAL suspensions under hypoxic
conditions supports the view that the increased release of ADE
by this segment is related to continued active transport during
ischemia. It is unlikely that both furosemide and ouabain would
have a similar direct effect on ADE transport per se. Further-
more, if inhibition of active transport reduced ADE production
and release, it is possible that ADE, itself, may limit further
ADE release by an action to inhibit active transport.
The majority of ADE release by OM suspensions under
non-hypoxic conditions is evidently derived from tissue other
than the mTAL, since the enriched mTAL suspension had little
ADE release under these conditions and one would assume that
the majority of tissue in the outer medulla is TAL. On the other
hand, the absolute increase in ADE release from OM and
mTAL suspensions under hypoxic conditions is similar [0.63
(OM) vs. 0.60 (mTAL) ng/pg protein], suggesting that it is the
mTAL predominately which increases ADE release under
hypoxic conditions. Further study will be required to substan-
tiate this view, however.
In summary, ADE is released by tissue in the rat outer
medulla including the TAL. Furthermore, this release is in-
creased to physiologically relevant concentrations by in vitro
hypoxic conditions that are compatible with that expected in
the renal medulla in vivo during ischemic injury. This increased
ADE release by hypoxia may have physiologic actions that
protect the medullary nephrons from ischemic injury. Further
studies, however, are necessary to clarify the mechanisms of
cellular ADE transport, to define a role for ADE in the
regulation of medullary transport processes, and to establish a
relationship between ADE levels and hypoxic or ischemic
damage.
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